PACIRA BIOSCIENCES, INC. Inventory Write-down
PACIRA BIOSCIENCES, INC. (PCRX) reported Inventory Write-down of $21.30 million for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:InventoryWriteDown · last filed 2019-02-28
- PACIRA BIOSCIENCES, INC. inventory write-down for the quarter ending 2017-03-31 was $21.30M.
- PACIRA BIOSCIENCES, INC. inventory write-down for the quarter ending 2016-12-31 was -$1.20M.
- PACIRA BIOSCIENCES, INC. inventory write-down for the quarter ending 2016-09-30 was $21.90M.
- PACIRA BIOSCIENCES, INC. inventory write-down for fiscal 2016 was $20.70M.
- PACIRA BIOSCIENCES, INC. inventory write-down for fiscal 2012 was $200.00K.
| Period end | Inventory Write-down 3 month | Inventory Write-down 3 month as first filed | Inventory Write-down 6 month | Inventory Write-down 9 month | Inventory Write-down 12 month |
|---|---|---|---|---|---|
| 2017-03-31 | $21.30M 10-Q · filed 2017-05-04 | $20.10M derived: sum of 2 quarters · filed 2019-02-28 | $42.00M derived: sum of 3 quarters · filed 2019-02-28 | ||
| 2016-12-31 | -$1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $20.70M derived: sum of 2 quarters · filed 2019-02-28 | $20.70M 10-K · filed 2019-02-28 | ||
| 2016-09-30 | $21.90M 10-Q · filed 2017-11-08 | $21.30M 10-Q · filed 2016-11-02 | $21.90M 10-Q · filed 2016-11-02 | ||
| 2012-12-31 | $200.00K 10-K · filed 2013-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |